a Phase I trial in patients with mild-to-moderate plaque psoriasis treatment with ASC50.
Latest Information Update: 06 Jun 2025
At a glance
- Drugs ASC 50 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
Most Recent Events
- 06 Jun 2025 New trial record
- 22 May 2025 According to the Ascletis Media Release, comoany announces the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for a Phase I trial for ASC50 for the treatment of mild-to-moderate plaque psoriasis. and expects to initiate dosing in the third quarter of 2025.